We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Merck KGaA (PK) | USOTC:MKKGY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.51 | 1.41% | 36.61 | 36.44 | 36.64 | 36.80 | 36.19 | 36.2515 | 24,662 | 21:28:59 |
From May 2019 to May 2024
By Cecilia Butini
Merck KgaA said Monday that it has signed agreements with Canadian cell therapy firm PanCELLa Inc. and with U.S.-based biotechnology company Takara Bio USA, Inc. to license them its CRISPR genome-editing technology.
The German health-care company said licensing of the technology--which allows for the cutting of portions of DNA in order to make changes--has the goal of accelerating drug discovery research in order to develop new therapies.
PanCELLa will use Merck's CRISPR patent in the development of therapeutics with genetically modified cell lines, the company said.
Under the agreement, Takara Bio will use Merck's CRISPR integration and vector technologies for the development of its own vector products and cell engineering services, Merck said. In molecular biology, vectors are used to carry genetic material into cells.
Merck didn't disclose payment details related to the licensing agreements.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
October 12, 2020 09:10 ET (13:10 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck KGaA (PK) Chart |
1 Month Merck KGaA (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
